Recombinant Anti-CD64 x Anti-GD2 VHH BispecificAntibody (IgG-VHH) (IGVHH-037)

Recombinant Anti-CD64 x Anti-GD2 Bispecific Antibody (IgG-VHH) is designed to be expressed as a LC and an extended HC with VHH moiety linked to the C terminus. It is a symmetric bispecific and tetravalent molecule, bivalent for each antigen specificity, 2+2 antigen-binding valency. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD64 & GD2

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Neuroblastoma; Osteosarcoma; Melanoma; Solid tumors

Targets

Target 1

CD64

Gene ID

2209

UniProt ID

P12314

Alternative Names

FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI

Target 2

GD2

Alternative Names

Ganglioside GD2; GD2; Ganglioside; Disialoganglioside GD2

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD64 x Anti-GD2 VHH BispecificAntibody (IgG-VHH) (IGVHH-037). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD64 x Anti-GD2 VHH BispecificAntibody (IgG-VHH) (CAT#: IGVHH-037)

Specifications

Targets

Customer Reviews and Q&As